

# Statement



Submitted testimony of PhRMA  
Monday, February 14, 2011  
Before the Committees on  
Insurance and Real Estate  
Public Health  
And  
Human Services

PhRMA's Understanding of Raised Bill 6322

February 14, 2011

The Pharmaceutical Research and Manufacturers of America understands that the intent of Section 1 (b) of "An Act Concerning Prescription Drug Purchasing" is to combine for administrative purposes only the drug benefit for persons identified in subsection 1 (a) with persons eligible for medical assistance benefits (e.g., Medicaid; the HUSKY Plan, Part A and Part B; the HUSKY Plus programs, ConnPACE; the Charter Oak Health Plan; and the Connecticut AIDS drug assistance program). PhRMA understands that the intent of Raised Bill 6322, as laid out in Section 1(b), is not to combine medical assistance patients with other state and non-state public employees for the purpose of purchasing prescription drugs or delivering healthcare benefits.

PhRMA understands the delivery of the medical assistance benefits will remain separate from benefits received by persons described in Section 1 (a). This means that the P and T Committee for Medicaid will remain, and that the existing Preferred Drug List (PD) system will remain in place as well as the patient protections that are long-established in the Medicaid program such as the ability for patients to stay on medications prescribed by physicians (continuity of care) and the ability for physicians to successfully determine which medication is best for the patient.

Thank you for the opportunity to comment on this proposal.